INVENTIVA SA (IVA.PA) Stock Price, Forecast & Analysis
EPA:IVA • FR0013233012
IVA.PA Key Statistics, Chart & Performance
The current stock price of IVA.PA is 5.49 EUR. In the past month the price increased by 9.8%. In the past year, price increased by 89.97%.
IVA.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IVA.PA. When comparing the yearly performance of all stocks, IVA.PA is one of the better performing stocks in the market, outperforming 96.47% of all stocks.
IVA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IVA.PA. IVA.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
IVA.PA Financial Highlights
Over the last trailing twelve months IVA.PA reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -74.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA.PA Forecast & Estimates
15 analysts have analysed IVA.PA and the average price target is 13.24 EUR. This implies a price increase of 141.18% is expected in the next year compared to the current price of 5.49.
For the next year, analysts expect an EPS growth of 45.26% and a revenue growth 6.05% for IVA.PA
IVA.PA Ownership
IVA.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 26.84 | 42.155B | ||
| ARGX | ARGENX SE | 25.91 | 40.348B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.218B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.129B | ||
| GXE | GALAPAGOS NV | N/A | 1.914B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| NANO | NANOBIOTIX | N/A | 1.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About IVA.PA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 116
Phone: 33380447500
INVENTIVA SA / IVA.PA FAQ
What does INVENTIVA SA do?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the current price of IVA stock?
The current stock price of IVA.PA is 5.49 EUR. The price decreased by -1.08% in the last trading session.
Does INVENTIVA SA pay dividends?
IVA.PA does not pay a dividend.
How is the ChartMill rating for INVENTIVA SA?
IVA.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for IVA stock?
The Revenue of INVENTIVA SA (IVA.PA) is expected to grow by 6.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.